EcoDrugPlus

Potassium Two Pore Domain Channel Subfamily K Member 3

Ensembl ID : ENSBSLG00000023839
Gene Symbol: KCNK3
3 Cross references
203 Possible Orthologues:

Potassium Two Pore Domain Channel Subfamily K Member 9

Ensembl ID : ENSBSLG00000003967
Gene Symbol: KCNK9
3 Cross references
219 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily A Member 5

Ensembl ID : ENSBSLG00000001717
Gene Symbol: KCNA5
3 Cross references
170 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3

Ensembl ID : ENSBSLG00000025857
Gene Symbol: KCND3
3 Cross references
190 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily D Member 3-Like

Ensembl ID : ENSBSLG00000013133
Gene Symbol: LOC114858527
3 Cross references
194 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSBSLG00000024782
Gene Symbol: KCNH2
3 Cross references
186 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 6-Like

Ensembl ID : ENSBSLG00000006169
Gene Symbol: LOC114846103
2 Cross references
154 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily H Member 7-Like

Ensembl ID : ENSBSLG00000019453
Gene Symbol: LOC114844362
2 Cross references
157 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 2-Like

Ensembl ID : ENSBSLG00000020721
Gene Symbol: LOC114858961
3 Cross references
184 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Kqt Member 5-Like

Ensembl ID : ENSBSLG00000016785
Gene Symbol: LOC114870672
2 Cross references
200 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSBSLG00000005199
Gene Symbol: KCNQ2
3 Cross references
184 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSBSLG00000002178
Gene Symbol: PSEN2
3 Cross references
206 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).